Horizon Therapeutics (NASDAQ: HZNP)
Some price data may be temporarily unavailable.
Key Data Points
Horizon Therapeutics Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Horizon Therapeutics Company Info
Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.
News & Analysis
Why Horizon Therapeutics Stock Is Crashing Today
The FTC is reportedly gearing up to block the drugmaker's takeover by Amgen.
Why Horizon Therapeutics Stock Is Soaring Today
Amgen's planned acquisition of Horizon could close in the first half of next year.
Why Horizon Therapeutics Stock Is Skyrocketing Today
Three big drugmakers could be interested in acquiring Horizon.
Why Horizon Therapeutics' Shares Rose 11.32% on Wednesday
The company released encouraging year-end guidance.
This Therapeutics Company Is Eyeing Zero Competition for the Next 5 Years
If production setbacks can be avoided, gains should be in sight.
3 Reasons to Buy Horizon Therapeutics Stock and 1 Not To
Horizon Therapeutics's shares are up almost 200% over the past 12 months, buoyed by mind-boggling sales of its new blockbuster drug.
Does the Best Biopharma to Work For in 2020 Belong in Your Portfolio?
Guiding for 25% growth in 2021 and with a clear path for future growth, there appears to be continued good times for shareholders of Horizon Therapeutics
Why Horizon Therapeutics Stock Jumped Today
The biopharmaceutical company released its latest quarterly update.
Financial Health
General
Q2 2023 | YoY Change |
---|
Revenue Growth Rate
Earnings Per Share Growth Rate
Assets
Q2 2023 | YoY Change |
---|
Liabilities
Q2 2023 | YoY Change |
---|
Ratios
Q2 2023 | YoY Change |
---|
Cash Flow
Q2 2023 | YoY Change |
---|
Valuation
Q2 2023 |
---|
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.